23:27 , Jun 14, 2018 |  BC Innovations  |  Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and Rv1733c....
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
01:24 , Jan 18, 2018 |  BC Extra  |  Preclinical News

Chromosomal instability can trigger metastasis via STING activity

A paper published in Nature brings into question the safety and efficacy of activating the transmembrane protein 173 (STING; TMEM173) pathway -- which triggers immune responses in the presence of cytosolic DNA -- in cancers...
02:05 , Dec 14, 2017 |  BC Week In Review  |  Clinical News

Aduro discontinues development of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and ovarian cancer. Aduro said it will now focus...
00:09 , Dec 13, 2017 |  BC Extra  |  Clinical News

Aduro discontinues development of CRS-207

Aduro Biotech Inc. (NASDAQ:ADRO) said it will discontinue development of CRS-207 based on "insufficient clinical activity" in Phase I/II trials of the candidate to treat mesothelioma and ovarian cancer. Aduro said it will now focus...
22:09 , Dec 1, 2017 |  BC Week In Review  |  Financial News

Mavupharma raises 20M in series A round for STING modulators

Mavupharma Inc. (Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma is developing orally bioavailable, non-nucleotide agonists of the transmembrane protein 173 (STING; TMEM173) pathway...
23:08 , Nov 29, 2017 |  BC Extra  |  Financial News

Mavupharma raises $20M series A for STING

Mavupharma Inc. (Kirkland, Wash.) raised $20 million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma is developing orally bioavailable, non-nucleotide agonists of the transmembrane protein 173 (STING; TMEM173) pathway...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
15:41 , Oct 6, 2017 |  BC Week In Review  |  Company News

Nimbus and Celgene partner for TYK2, STING programs

Nimbus Therapeutics LLC (Cambridge, Mass.) and Celgene Corp. (NASDAQ:CELG) partnered to develop antagonists of tyrosine kinase 2 (TYK2) and transmembrane protein 173 (STING; TMEM173) to treat autoimmune diseases. The partners plan to develop small molecules...